source
- Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentDespite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.Fierce Biotech · 6h ago↗ source
- Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseasesPfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…